Abstract
BACKGROUND: Scalp micropigmentation (SMP) is emerging for camouflaging localized alopecia, yet standardized protocols and long-term efficacy data remain limited. AIMS: To evaluate technical parameters, clinical outcomes, and safety of SMP in diverse alopecia subtypes. METHODS: Ten patients (androgenetic alopecia: n = 6; scarring alopecia: n = 4) underwent a standardized three-session SMP protocol. Technical refinements included zone-specific needle selection (single/triple point), hierarchical pigment deposition (prioritizing thick-haired regions), and randomized distribution to avoid uniformity. Pigment density was incrementally adjusted (30%→70%→100% of natural follicular spacing). Adherence to a zero-bleeding protocol ensured epidermal-upper dermal depth. Outcomes were assessed via visual density score (VDS, 0~10) and patient satisfaction score (PSS, 0~3). RESULTS: All patients achieved significant cosmetic improvement. Immediate posttreatment VDS averaged 8.7 ± 1.1, with androgenetic cases scoring higher (9.1 ± 0.5). At 6-month follow-up, VDS declined modestly (7.7 ± 1.4), though scarring alopecia showed greater fading (Δ = 1.6 vs. Δ = 0.9 in androgenetic, p = 0.03). Patient satisfaction was high (mean PSS = 2.7/3), with 85.7% of androgenetic cases "very satisfied." Strong correlation existed between VDS and PSS (ρ = 0.91, p < 0.001). No adverse events occurred. CONCLUSIONS: SMP is a safe, minimally invasive solution for localized alopecia, providing sustained cosmetic improvement. Technical refinements in needle selection, pigment layering, and depth control optimize outcomes. Future studies should focus on long-term pigment retention and expanded cohorts.